共 25 条
- [2] Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center StudyTargeted Oncology, 2019, 14 : 689 - 697Jwa Hoon KimSun Young KimKyu-pyo KimTae Won KimSun Young ChaeHwa Jung KimJae Seung KimJin-Sook RyuDae Hyuk MoonJeong Eun KimYong Sang Hong
- [3] Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center StudyTARGETED ONCOLOGY, 2019, 14 (06) : 689 - 697Kim, Jwa HoonKim, Sun YoungKim, Kyu-pyoKim, Tae WonChae, Sun YoungKim, Hwa JungKim, Jae SeungRyu, Jin-SookMoon, Dae HyukKim, Jeong EunHong, Yong Sang
- [4] Authors' Reply to Yusuf Ziya Sener: "Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study"TARGETED ONCOLOGY, 2020, 15 (03) : 413 - 414Kim, Jwa HoonKim, Jeong EunHong, Yong Sang
- [5] Authors’ Reply to Yusuf Ziya Sener: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”Targeted Oncology, 2020, 15 : 413 - 414Jwa Hoon KimJeong Eun KimYong Sang Hong
- [6] Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluationANNALS OF ONCOLOGY, 2019, 30Kim, J. H.Kim, J. E.Kim, S. Y.Kim, K-P.Hong, Y. S.Kim, T. W.
- [7] The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center studyUROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (05) : 704 - 710Baldazzi, ValentinaTassi, RenatoLapini, AlbertoSantomaggio, CarmineCarini, MarcoMazzanti, Roberto
- [8] Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort studyJOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1497 - 1507Chen, CanLuo, XiTang, WenhuaGeng, HaofeiMartinez-Perez, JuliaPrice, TimothyKang, LiliLu, HonglianZhang, Yanling
- [9] Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use programBMC CANCER, 2016, 16Adenis, Antoinede la Fouchardiere, ChristellePaule, BernardBurtin, PascalTougeron, DavidWallet, JenniferDourthe, Louis-MarieEtienne, Pierre-LucMineur, LaurentClisant, StephaniePhelip, Jean-MarcKramar, AndrewAndre, Thierry
- [10] Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programBMC Cancer, 16Antoine AdenisChristelle de la FouchardiereBernard PaulePascal BurtinDavid TougeronJennifer WalletLouis-Marie DourthePierre-Luc EtienneLaurent MineurStéphanie ClisantJean-Marc PhelipAndrew KramarThierry Andre